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Cisplatin-based chemotherapy represents an effective treatment
for the majority of patients with advanced malignant germ cell
tumour. However, about 20% of the patients progress during or
after such chemotherapy and require salvage treatment (Mead et
al, 1992). A variety of salvage treatments have been established
which, in addition to platinum, usually include cytotoxic agents to
which the patient has not been exposed previously, such as ifos-
famide (Loehrer, et al, 1986), vinblastine (Loehrer et al, 1998,
doxorubicin (Lederman and Garnick, 1986), methotrexate (Levi et
al, 1990), actinomycin D (Levi et al, 1990) and paclitaxel (Motzer
et al, 1994).
High-dose chemotherapy (Broun et al, 1992; Siegert et al, 1994;
Beyer et al, 1996; Margolin et al, 1996) with stem cell support is
increasingly accepted as the treatment of choice for patients
progressing during or after primary chemotherapy for germ cell
malignancy. Disease-free survival rates of 40–50% have been
reported after such treatment which seems superior to the
20% disease-free survival rates obtained with ‘conventional’
chemotherapy schedules. Although the toxicity of high-dose
chemotherapy has decreased with increasing experience there
remains a considerable risk of severe and even lethal toxicity asso-
ciated with the treatment approach in these patients. Therefore,
until the superiority of a high-dose approach as salvage treatment
has been demonstrated in randomized trials, patients should not be
subjected to such treatment unnecessarily. It is thus important to
identify prognostic factors for salvage treatment for patients with
disease activity of their germ cell malignancy during or after
induction chemotherapy.
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Summary The aim of this study was to define prognostic parameters for survival in patients with malignant germ cell tumours progressing
after platinum-based induction chemotherapy with or without surgery. A total of 164 progressing patients (testicular: 83%, extragonadal: 17%)
were identified out of 795 patients treated with platinum-based induction chemotherapy for metastatic germ cell malignancy with or without
surgery. ‘Progressive disease’ included patients who had progressed after a previous partial or complete remission as well as patients who
failed primary therapy. Salvage chemotherapy consisted of ‘conventional’ platinum-based chemotherapy. Prognostic factors for survival were
assessed by uni- and multivariate analyses. The resulting prognostic model was validated in an independent data set of 66 similar patients.
For all 164 patients the median time from start of induction chemotherapy to progression was 10 months (range: 0–99). Thirty-eight (23%)
patients relapsed after 2 years. The 5-year survival rate for all progressing patients was 30% (95% confidence interval 23–38%). In the
univariate analysis the following factors most importantly predicted a poor prognosis: progression-free interval < 2 years: initial poor prognosis
category (MRC criteria), < CR to induction chemotherapy, initial treatment early in the 1980s and treatment given at a ‘small’ centre. Three
prognostic factors remained in the multivariate analysis: progression-free interval, response to induction treatment and the level of serum
human chronic gonadotrophin (hCG) and alpha fetoprotein (AFP) at relapse. One hundred and twenty-four patients could be classified on the
basis of these characteristics, Those patients with progression-free interval < 2 years, < CR to induction chemotherapy and high markers at
relapse (AFP >100 kU l–1 or hCG >100 IU l–1) formed a poor prognosis group of 30 patients, none of whom survived after 3 years. Patients
with at most two of these three risk factors formed a good prognosis group of 94 patients (76%) with a 47% (37–56%) 5-year survival. Thirty-
eight patients from the good prognosis group with a progression-free interval of >2 years had a 2-year survival of 74% (60–88%) and 5-year
survival of 61%. These prognostic groups were validated in the independent data set, in which 5-year survival rates in the good and poor risk
groups were 51% and 0% respectively. One-third of patients progressing during or after platinum-based induction chemotherapy for
metastatic germ cell malignancy may be cured by repeated ‘conventional’ platinum-based chemotherapy. Good prognosis parameters
are: progression-free interval of > 2 years, CR to induction treatment and normal or low serum markers at relapse (hCG < 100 IU l–1 and
AFP < 100 kU l–1). The results of high-dose salvage chemotherapy should be interpreted on the background of these prognostic factors.
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Few series have been published dealing with prognostic factors in
patients with recurrent malignant germ cell tumours, and most are
based on the experience of specialized institutions (Motzer et al,
1991; Horwich et al, 1993; Josefsen et al, 1993; Ledermann et al,
1994; Gerl et al, 1995). The aim of the present study was to establish
prognostic factors based on a series of patients presenting to
unselected oncological units. Such analyses may represent an appro-
priate background for the interpretation of the results of modern
high-dose salvage chemotherapy and may also assist the clinician to
identify future patients for risk-adapted salvage treatment.
PATIENTS AND METHODS
In a previously published study prognostic factors were identified
in 795 patients with advanced germ cell tumours (Mead et al,
1992). The present series represents a further analysis of those
patients who progressed during or following cisplatin-based
induction chemotherapy. This includes patients who never
achieved a response and those with new disease activity after
achieving a complete or partial response to primary chemotherapy.
All patients had been treated with first-line platinum-based
chemotherapy between 1982 and 1986.
As a rule patients with residual post-chemotherapy masses
underwent surgery to remove them, and they received adjuvant
cisplatin-based chemotherapy if residual germ cell malignancy
was demonstrated in the post-chemotherapy resection specimen.
Histological subtyping of the primary germ cell cancer was based
on the Pugh Classification: MTU: malignant teratoma undifferen-
tiated; MTI: malignant teratoma intermediate; MTT: malignant
teratoma trophoblastic; TD: teratoma differentiated. In 13 patients
with elevated serum AFP the malignant germ cell tumour could
not be subtyped histologically.
For the present study all patients had data on baseline character-
istics, and updated survival data. Seven centres provided further
retrospective data on their patients and recorded details of the
marker levels and sites of disease at progression. Based on the
number of patients entered into the original series (Mead et al,
1992) ‘large oncological units’ were separated from ‘small’ ones.
The former had contributed more than 75 patients with metastatic
non-seminoma as opposed to < 75 for ‘small’ oncological units.
This division was supported by patient entry by these centres into
other Medical Research Council (MRC) trials. All patients in this
study had received both induction and relapse chemotherapy at
their local centre; patients referred to centres participating in this
study for relapse treatment only were not included.
Complete response (CR) to treatment was defined as the clinical
and radiological absence of all tumour manifestations (including
normalization of serum alpha fetoprotein (AFP) – human chronic
gonadotrophin (hCG), or the complete resection of residual mature
teratoma or necrotic/fibrotic tumour tissue. Incomplete response
(IR) comprised patients with persistently elevated markers
(without serially rising values) or the histological demonstration of
residual cancer in resection specimen. Patients with unresected
residual tumour masses with normal tumour markers were
included in the category Partial remission (PR) marker negative.
Progression (PD) was defined as the development of new metas-
tases and/or clearly rising serum tumour markers.
Factors predictive of survival from the date of progression were
then identified. Potential prognostic factors included patient char-
acteristics at initial diagnosis (site and extent of metastatic disease
sites), response to initial chemotherapy, duration of relapse-free
interval, and patient characteristics at relapse. An independent data
set of 66 patients (provided by Dr A Gerl, Munich) was available
on which to test the resulting prognostic models.
Survival times were measured from the date of diagnosis of
progression to the date of death or date last seen. Survival curves
were compared using the logrank test, and Cox’s proportional
hazards regression model was used to identify independent
Table 1 Pretreatment characteristics and induction treatment
Characteristic Group Number of patients
Histologya MTU 71
MTI 52
MTT 21
TD 7
Unspecified NSGCT 13
Primary tumour site Testis 136
Retroperitoneal 20
Mediastinal 5
Unknown 3
Prognostic group (MRC) Good 57
Poor 106
Not classifiable 1
Age Median 30 years
Range 14–83 years
Treatment centres Largeb 90
Small 74
Primary chemotherapyc PVB 14
BEVIP 4
POMB/ACE 32
Cisplatin+etoposide+others 114
Number of courses 2–3 7
46 3
5–6 52
>6 29
not known 13
Response to induction  Complete response 53
treatment Incomplete response 52
Partial response, marker
negative 48
Progressive disease 11
Total patients 164
aPugh classification (see text). b>75 patients with metastatic non-seminoma
in the original study (see text). cP: platinum, V: vinblastine, B: bleomycin, 
E: etoposide, I: ifosfamide; O: Oncovin, M: methotrexate, A: actinomycin D,
C: cyclophosphamide.
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Figure 1 Time from start of initial chemotherapy to relapse/progression1394 SD Fosså et al
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prognostic factors. A forward stepwise variable selection proce-
dure was used.
RESULTS
One hundred and sixty-four of the 795 patients (21%) relapsed. Of
these, 116 (71%) have died and the median follow-up time of those
still alive is 8.5 years (range 1–12.5 years). Patient characteristics
at the time of initial diagnosis and details of primary chemotherapy
are described in Table 1. The primary tumour site was identified in
our study as the testis in 83% of the patients. Fifty-seven patients
belonged at the start of induction chemotherapy to the good and
106 to the poor prognosis groups as defined by the previous MRC
study (Mead et al, 1992). (One patient could not be classified.) The
majority of patients received at least four courses of combination
chemotherapy including both cisplatinum and etoposide. Twenty-
one of the 164 patients had undergone adjuvant chemotherapy as
histology of masses had demonstrated viable residual cancer.
Detailed data on characteristics at relapse were available for a
subset of 110 patients, and these are included in Table 2. Relapse
treatment was given between 1982 and 1991. In 103 patients a
great variety of salvage regimens were employed, eighty-nine
patients received cisplatin-based combinations, and no patient
received high-dose chemotherapy. Ifosfamide-containing salvage
Table 2 Univariate survival analysis from diagnosis of relapse
Parameter Number of patients 2-Year survival rate Log-rank
c2b P-valuec
Prognostic group at 1° diagnosis (MRC)
Good 57 51% 9.2 0.0024
Poor 106 32%
Site of primary tumour
Testis 136 38% 0.03 0.86
Extragonadal 28 41%
Age
<30 99 41% 1.15 0.28
30–39 42 40% (t)
40–49 13 31%
³50 10 20%
Response to induction treatment
Complete 53 58% 43.4 ≤0.0001
Incomplete 52 27% (3 d.f)
PR marker negative 48 37%
Progression 11 0%
Time from initiation of primary therapy to
progression (months)
<6 37 22% 20.4 <0.0001
6–12 57 28% (t)
13–24 32 33%
25–36 15 73%
>36 23 74%
hCG at relapse (IU l–1)a
Normal 57 39% 1.40 0.24
<100 23 48% (t)
100–1000 19 32%
>1000 11 27%
AFP at relapse (kU l–1)a
Normal 55 45% 3.65 0.056
<100 33 37% (t)
100–1000 13 23%
>1000 9 22%
Year of relapse treatment
Before 1986 94 29% 7.15 0.008
1986–1991 70 51%
Treatment centre
‘Large’ 90 45% 5.12 0.02
‘Small’ 74 29%
Sites of relapse (1)*
Markers only 16 38%
Abdominal nodes 29 45%
Mediastinal/neck nodes (± abdo nodes) 8 63% 3.08 0.54
Lung (± abdo/med/neck nodes) 28 36% (4 d.f)
Other visceral mets (± other sites) 29 28%
Sites of relapse (2)a
No lung or other visceral mets 53 45% 1.03 0.31
Lung or other visceral mets present 57 32%
aData available in a subgroup of 110 patients. bChi square on 1 d.f. unless otherwise stated. c(t) indicates chi square test for trend.Salvage treatment in recurrent germ cell malignancy 1395
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chemotherapy was given to only 15 patients. No detailed informa-
tion is available on the doses of the drugs and intervals between
cycles. Thirty-two patients had surgery to remove residual masses
in addition to chemotherapy. Seven patients did not receive salvage
chemotherapy due to patient refusal (three patients), rapid death
before start of chemotherapy (two patients), radiotherapy only
(one patient) or surgery only (one patient). This latter patient had
progressed with a 3-cm large retroperitoneal mass and raised AFP
(48 kU l–1) 15 months after discontinuation of primary
chemotherapy. He was salvaged by surgery without further
chemotherapy. The remaining six patients all died within 7 months
of the diagnosis of their progression.
The role of surgery in addition to salvage chemotherapy was
analysed specifically: of 31 patients in whom a residual mass
was completely resected immediately before or after salvage
chemotherapy, 16 are alive after 5 years. In 36 patients who after
salvage chemotherapy had a complete radiological response, the 3-
year survival rate was only 14%, whereas those with residual mass
left unresected (n = 32) had a 3-year survival rate of 31%.
The median time to progression from the start of initial induc-
tion chemotherapy (Figure 1) was 10 months (range 0–99 months)
for all patients (n = 164) and the subset with additional data on
progression characteristics (n = 110). Eleven patients progressed
within 4 weeks from the date of the end of last chemotherapy cycle
(‘absolutely cisplatin refractory patients’). In 38 patients (23%)
renewed tumour activity developed more than 2 years after the
start of induction treatment. Nineteen of these ‘late’ relapses
occurred among the 53 patients with a CR to induction treatment.
Seven of the above 38 patients with progression > 2 years after
induction chemotherapy occurred amongst 52 incompletely
responding patients, and 12 patients with late progression were
from 48 patients belonging to the PR marker negative category.
Median survival time following progression was 1 year (Figure 2),
and the 5-year survival rate for all patients following progression
was 30% (95% confidence interval (CI) 23.4–37.6%). Ten
progressing patients had increased serum markers more than 2
years after primary chemotherapy. With a minimum follow-up of 3
years, only three of these ten patients have died.
Table 2 gives the results of the univariate analyses. The most
important factors indicating a poor prognosis were a short progres-
sion-free interval, less than complete response to induction
chemotherapy (± surgery), poor prognostic group at diagnosis, as
defined by MRC criteria (Mead et al, 1992), treatment for relapse
commencing in the early 1980s and treatment given at a ‘small’
centre.
All the factors described in Table 2, together with age (as a
continuous variable) and primary tumour site (testis vs extra-
gonadal) were included in the multivariate analysis. Patients with
missing data on any factor were excluded on a case-by-case basis.
In addition, progression-free interval, AFP and hCG at the time of
progression were considered using the categories defined in Table
2, and also using binary cut-points. The cut-points chosen sepa-
rated complete responders from all other response categories,
progression-free interval greater or less than 2 years, AFP at
progression above or below 100 kU l–1 and hCG at progression
above or below 100 IU l–1. A further binary variable was defined
which identified patients with neither marker raised above these
limits.
The multivariate analysis (Table 3) identified three factors of
independent prognostic importance (P-value for inclusion < 0.1);
progression-free interval, response to induction treatment and
marker levels. The hazard ratios for patients with either IR or PR
marker negative were very similar. The small group of six patients
with PD had the poorest outcome. As the hazard ratios for the
three above factors were dissimilar, a number of prognostic
models were considered which applied different weightings to the
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Figure 2 Time from first relapse/progression to death
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Figure 3 Survival by prognostic group – developmental data set. (—) Good
risk (≤ two risk factors) n = 94; (- -) Poor risk (all three risk factors) n = 30
Figure 4 Survival by prognostic group – test data set. (—) Good risk (≤ two
risk factors) n = 49; (- -) Poor risk (all three risk factors) n = 171396 SD Fosså et al
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Table 3 Cox regression analysis: final model
Variable Regression coefficient (s.e.) Hazard ratio
Time to progression (reference category) 1
(≤ 2 vs > 2 years) 0.80 (0.34) 2.22
High markers at relapse (reference category) 1
AFP > 100 ku l–1 and/or hCG > 100 IU l–1) 0.60 (0.25) 1.82
Response to induction treatment 1
CR (reference category)
IR 0.42 (0.31) 1.52
PR marker negative 0.39 (0.31) 1.49
PD 1.46 (0.48) 4.28
Table 4 Validation data summary: independent data set of 66 patients
Characteristic Group Number of patients
Response to induction CR to chemo ± surgery 37
treatment Elevated markers/residual malignant tumour 25
Residual mass unresected (markers normal) 4
Time to progression ≤2 years 53
>2 years 13
AFP at relapse (km l–1) Normal 41
≤ 100 7
>100 18
hCG at relapse (IU l–1) Normal 38
≤ 100 11
>100 17
Sites of relapse
Abdomen No 34
Yes 32
Lung No 43
Yes 23
Mediastinum No 61
Yes 5
Extrapulmonary No 42
Yes 24
Year of relapse treatment 1980–1985 32
1986–1990 21
1990–1995 13
Total patients 66
Table 5 Efficacy of salvage treatment in (excluding high-dose regimens) in patients with malignant non-seminomatous germ cell tumours,
progressing/relapsing after cisplatin-based induction chemotherapy
1st Author Year No. of patients Chemotherapy CR Long-term
schedule rate survival
Loehrer 1986 48 VIPa,b 33% NAc
Motzer 1991 94 Variousd 23% 15%
Josefsen 1993 55 Various NA 23%
Horwich 1993 105 Various NA 35%
Ledermann 1994 38 Variouse 47% 46%
Motzer 1994 31 Paclitaxel 10% NA
Gerl 1995 67 Variousf NA 37%
McCaffrey 1997 56 VIP/VeIP 36% 40%
Loehrer 1998 135 VeIP 50% 46%
Fosså Present series 164 Various NA 30%
a V: VP-16, E: Etoposide, I: Ifosfamide, P: cis-platin, Ve: Vinblastine (VelbeR), B: Bleomycin. bAfter P Ve B. cNot available. dMostly BEP after P Ve B. eContaining
vincristine, MTX, actinomycin D. fIfosfamide in 38 patients.Salvage treatment in recurrent germ cell malignancy 1397
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various factors. As the overall survival for patients with and
without information on markers at progression was very similar,
patients without marker information were also included in the
models where possible. The simplest model separated patients into
two groups on the basis of the number of adverse risk factors they
had. Given the three risk factors:
• progression-free interval < 2 years
• < CR to induction chemotherapy
• high markers at progression (AFP >100 kU l–1 and/or
hCG > 100 IU l–1)
Patients with all three had a very poor prognosis; this group
comprised 30 patients with a median survival time of 7 months and
a 2-year survival rate of 7% (95% CI 0–15%). None of these
patients survived beyond 3 years. Ninety-four patients (81 with
data on all three factors and a further 13 without data on markers at
relapse), that is those with at most two risk factors, formed a ‘good
prognosis’ group with a 2-year survival rate of 56% (95% CI
46–66%), and a 5-year survival rate of 47% (37–56%). The
survival curves for these two groups are shown in Figure 3. It was
possible to subdivide the good prognosis group further, on the
basis of progression-free interval – the 38 patients with a progres-
sion-free interval of more than 2 years had a 2-year survival rate of
74% (60–88%), while those with a shorter progression-free
interval has a 2-year survival rate of 45% (32–58%).
Model validation
The independent data set was used to test the prognostic model.
The data included 66 patients with disease progression during
or after platinum-based induction chemotherapy, none of whom
received high-dose therapy on progression. Sixty patients received
‘conventional’ regimens for progressive germ cell malignancy (of
whom 40 received cisplatin- and ifosfamide-based regimens with
either vinblastine or etoposide), while six were treated with
surgery and/or radiotherapy alone. Forty-three patients have died;
of the 23 alive, median follow-up is 8 years (range 6 months to 14
years). The characteristics of these patients are described in Table
4, using the same criteria for response as defined for the principle
data set collected by the MRC.
The two-group prognostic model was applied to this data, and
the resulting survival curves are shown in Figure 4. The number of
patients falling into the good and poor risk groups were 49 (74%)
and 17 (26%) and the corresponding 2-year survival rates were
58% and 0% (43–72%), respectively. Five of the patients within
the good risk group were categorized as ‘absolutely platinum
refractory’, whereas this was the case for six patients within the
poor prognosis group.
DISCUSSION
Progressive germ cell malignancy
Progression after IR/PR marker negative or relapse after CR was
observed in 164 (21%) of the original 795 patients with malignant
germ cell tumours treated with cisplatin-based induction
chemotherapy. This percentage is comparable to other reports
(Motzer et al, 1991; Horwich et al, 1993; Josefsen et al, 1993; Gerl
et al, 1995). Although about 70% of the cases of progression
occurred within the first year after the start of induction treatment,
reactivation of the disease was observed in 23% patients after 2
years. This observation together with the possibility of cure in
patients with ‘late’ progression indicate the necessity to continue
regular follow-up in patients with metastatic germ cell tumours for
at least 5 years and probably longer.
Induction chemotherapy
Four 3-weekly cycles of BEP (bleomycin 90 mg cycle–1, etoposide
500 mg m–2 cycle–1, cisplatin 100 mg m–2 cycle–1) are today consid-
ered to be the standard treatment with metastatic malignant germ
cell tumour. The PVB (cisplatin, vinblastine, bleomycin) combina-
tion used during the early 1980s has been shown to be significantly
inferior to the BEP combination both with regard to efficacy and
toxicity (Williams et al, 1987), whereas ifosfamide-containing
regimens have not proved to be superior as induction treatment
(Nichols et al, 1995). Carboplatin-based induction chemotherapy
is, however, less effective than BEP (Horwich et al, 1997). Failure
of induction chemotherapy may be due to primary or secondary
drug resistance or to insufficient dosing or incorrect drug selec-
tion. So far no study has addressed the role of induction
chemotherapy as regards the outcome of salvage treatment
(number of cycles, type, dose-intensity). In the present series data
were not available to evaluate any inadequacy of the induction
treatment in relapsing patients. In future studies concerning
relapsing patients, information on type and intensity of the induc-
tion treatment should be provided, and analysed with regard to its
prognostic significance.
Salvage treatment
The present analysis concentrates on prognostic factors evaluable
before salvage treatment. However, the importance of resection of
residual masses in patients with recurrent germ cell malignancies
is increasingly recognized (Cassidy et al, 1992). The present retro-
spective analysis supports this view, though the results have to be
interpreted having selection bias in mind.
It was not possible to study the role of the different salvage
chemotherapy regimens due to the considerable heterogeneity of
the drugs and regimens used. Today ifosfamide- and vinblastine-
containing combinations (Loehrer et al, 1998) would be those
drugs most frequently selected in patients who have not received
these agents during their induction treatment (or a methotrexate-
containing regimen (Levi et al, 1990)). However, only 15 of our
patients received ifosfamide. Recently, paclitaxel (Motzer et al,
1994) has been identified as an active drug for salvage
chemotherapy of patients with relapsing germ cell tumours. The
use of these drugs after a standard BEP regimen (bleomycin,
etoposide, cisplatin) would, if at all, have increased the overall
outcome of salvage treatment as compared to the present series,
but with one or little impact on the presented prognostic pretreat-
ment factors.
The overall long-term survival (and probably cure rate) for our
progressing patients was 30% which is comparable to other reports
(Table 5). On the other hand, McCaffrey et al’s (1997) survival
curves visualize an almost 40% long-term overall survival rate
in patients treated with ifosfamide-containing cisplatin-based
salvage chemotherapy. A different composition of prognostic
groups in large versus small institutions may be one reason for
such differences. A further reason for varying results may be that
contrary to McCaffrey et al’s report, we analysed our series
according to the ‘intention to treat’ principle. This included five1398 SD Fosså et al
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patients who finally refused all treatment (three) or died before the
start of salvage chemotherapy (two).
The use of high-dose chemotherapy with carboplatin, etoposide
and ifosfamide together with haematopoietic stem cell support has
been explored in single institution phase II studies (Broun et al,
1992; Siegert et al, 1994; Margolin et al, 1996). A multicentre
experience has been analysed recently by Beyer et al (1996)
Several of these studies have emphasized the role of patient selec-
tion and of prognostic factors. Beyer et al (1996) have determined
independent poor prognosis parameters which made subgrouping
of progressing patients possible with respectively 50%, 30% and
4% overall long-term survival after high-dose chemotherapy for
treatment of first or subsequent relapse. These authors identified
the following poor prognosis parameters: mediastinal non-semino-
matous primary tumour, progressive disease before high-dose
chemotherapy, disease refractory to conventional-dose cisplatin,
hCG >1000 IU l–1. Using conventional cisplatin-based salvage
chemotherapy Gerl et al (1995), Josefsen et al (1993) and Motzer
et al (1991) identified a complete response to induction treatment
as an additional positive independent prognostic factor which is
confirmed in the present study.
In contrast to the report by Nichols et al (1994) on relapsing
patients (after CR) a long interval from induction therapy to first
progression proved to be the most powerful prognostic parameter.
This discrepancy is difficult to explain but may be related to
slightly different selection of patients: our analysis include patients
with primary IR/PR who progressed after > 2 years, whereas
Nichols et al only discuss patients with initial CR. Baniel et al
(1995) emphasized the role of surgery in patients with late relapses
and suggested that chemotherapy was only limitedly effective in
these patients, progressing after > 2 years. Our series does not
allow an analysis concerning these aspects as the majority of
evaluable patients underwent both surgery and chemotherapy. Our
finding supported by data from Horwich et al (1993) although it
should be noted that some of these patients were included in our
data set also. Interestingly, raised markers in patients with a long
progression-free interval were not an adverse feature, but this was
the case when the progression-free survival was short.
The good prognosis group comprised 94 patients (76%) and had
a 47% 5-year survival when treated with ‘conventional’ salvage
chemotherapy. This survival rate is quite comparable with the
results of high-dose chemotherapy followed by stem cell support
which is increasingly being applied in progressing patients. Our
observations thus strongly indicate the need for a randomized trial
in these patients in order to prove any superiority of the high-dose
chemotherapy approach. On the other hand, the survival in patients
belonging to the poor prognostic group is dismal if ‘conventional’
salvage chemotherapy is applied. These patients should probably
be offered more intensive treatment regimens than available in the
1980s, with the use of stem cell support if possible (Broun et al,
1992; Siegert et al, 1994; Beyer et al, 1996; Margolin et al, 1996).
The present observations are not directly comparable with the
prognostic parameter analysis performed by Beyer et al (1996).
Most of Beyer et al’s patients had developed progressive disease
twice when receiving high-dose chemotherapy. Beyer et al
assessed survival from the time when high-dose treatment was
given. The patients from the present series had progressed only
once after start of induction chemotherapy, and their survival was
calculated from the time of their first progression. In the present
series all progressing patients were included in the analysis,
even those who did not receive (planned) salvage chemotherapy,
whereas all patients evaluated by Beyer et al had been treated with
high-dose chemotherapy. Furthermore, as also pointed out by
Beyer et al, 65 of their patients received high-dose chemotherapy
while responding to conventional chemotherapy (even CR),
whereas all our patients had progressed at commencement of
salvage treatment. However, Beyer et al’s results of salvage high-
dose chemotherapy, although not directly comparable with the
present series, represent a clear indication that high-dose
chemotherapy may be effective in some patients who relapse
despite conventional salvage treatment. This aspect will be further
dealt with in a future case control study.
In conclusion, about 20% of the patients with metastatic non-
seminoma are not cured by standard conventional induction
chemotherapy. The overall 5-year survival rate for these patients
is 30% after conventional cisplatin-based salvage chemotherapy
used in a multicentre setting. The group consists of two prognostic
subgroups: a good prognosis group (about 75%) with a 5-year
survival rate of 47% and a poor prognosis group (about 25%) with
no patient surviving after 3 years. The results from non-random-
ized new approaches of salvage therapy should be interpreted on
the background of the above prognostic groups, keeping in mind
that about one-third of the progressing patients may be cured by
‘conventional’ means.
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